Metal-Based Drugs
Volume 2009 (2009), Article ID 348916, 11 pages
http://dx.doi.org/10.1155/2009/348916
In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent
1Ludwig Boltzmann Cluster Translational Oncology, Operngasse 6/5, 1010 Vienna, Austria
2Medical University of Vienna, Department of Gynecology, Waehringer Guertel 18-20, 1090 Vienna, Austria
3Institute of Pharmacy, University of Greifswald, Friedrich-Ludwig-Jahn-Strasse 17, 17487 Greifswald, Germany
Received 25 November 2008; Revised 23 February 2009; Accepted 15 April 2009
Academic Editor: Mauro Coluccia
Copyright © 2009 Ulrike Olszewski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Platinum(IV) compounds like oxoplatin (cis, cis, trans-diammine-dichlorido-dihydroxido-platinum(IV)) show increased stability and therefore can be applied orally. In a panel of 38 human cancer cell lines this drug induced S-phase arrest and cell death with